## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/509,952	10/04/2004	Reddy Bandi Parthasaradhi	H1089/20015	3097
	7590 01/17/2008 ISE, BERNSTEIN,	EXAMINER		
COHEN & POR	KOTILOW, LTD.	CHANG, CELIA C		
11TH FLOOR, SEVEN PENN CENTER 1635 MARKET STREET			ART UNIT	PAPER NUMBER
PHILADELPHI	IIA, PA 19103-2212		1625 .	
			<u> </u>	
	,		NOTIFICATION DATE	DELIVERY MODE
			01/17/2008	ELECTRONIC

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patents@crbcp.com

		Application No.	Applicant(a)		
		Application No.	Applicant(s)		
		10/509,952	PARTHASARADHI ET AL.		
	Office Action Summary	Examiner	Art Unit		
		Celia Chang	1625		
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply				
A SHOP WHICH - Extension after SI - If NO pe - Failure to Any rep	RTENED STATUTORY PERIOD FOR REPLY EVER IS LONGER, FROM THE MAILING DA ons of time may be available under the provisions of 37 CFR 1.13 (6) MONTHS from the mailing date of this communication. A priod for reply is specified above, the maximum statutory period we or reply within the set or extended period for reply will, by statute, by received by the Office later than three months after the mailing patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION (6(a). In no event, however, may a reply be timedia apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE!	I. hely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status					
2a)⊠ T 3)⊡ S	esponsive to communication(s) filed on <u>09 Notestine</u> his action is <b>FINAL</b> . 2b) This ince this application is in condition for allowant losed in accordance with the practice under E	action is non-final. ace except for formal matters, pro			
Dispositio	n of Claims				
4a 5)□ C 6)⊠ C 7)□ C	laim(s) 1-4 is/are pending in the application. a) Of the above claim(s) is/are withdraw slaim(s) is/are allowed. claim(s) 1-4 is/are rejected. claim(s) is/are objected to. claim(s) are subject to restriction and/or				
Application	n Papers		•		
10)□ TI A R	ne specification is objected to by the Examine ne drawing(s) filed on is/are: a) acception and acception and acception and acception and acception and acception are declaration as objected to by the Examine oath or declaration is objected to by the Examine acception.	epted or b) objected to by the liderawing(s) be held in abeyance. See ion is required if the drawing(s) is object.	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).		
Priority un	der 35 U.S.C. § 119	•			
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
Attachment(s	s) of References Cited (PTO-892)	4) 🔲 Interview Summary	(PTO-413)		
2) Notice (3) Information	of Neterlehices Gited (* 10-032) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO/SB/08) No(s)/Mail Date	Paper No(s)/Mail Do 5) Notice of Informal F 6) Other:	ate		

10/509,952 Art Unit: 1625

## **DETAILED ACTION**

- 1. Response filed by applicants dated Nov. 9, 2007 has been considered carefully. Claim 1-4 are pending. No amendment was made.
- 2. The rejection of claims 1 and 4 under 35 USC 102(e) over US 6,649,765 is maintained for reason of record.

Applicants argued that the term "concentration" is removal of solvents, therefore, the solvents of the prior art process is methylene dichloride, then, methanol not methylene dichloride with methanol. Applicants argued that the default description of a solid material is not inherently "amorphous".

Two chemical handbook are hereby attached for applicants convenience. The CRC handbook defines amorphous as "having no definite order of crystalline structure". Therefore, if a solid was not defined to have "definitive crystalline order" is amorphous. The Hackh's chemical dictionary is provided to show that the term "concentrate" chemically is the increase of solute content, thus, *not removal of all solvent*.

The mis-interpretation of the terms by attorney is improper. The rejection is proper and maintained for the printed reference read on the claims.

3. The rejection of claims 1-4 under 35 USC 103(a) over Vijyadhar et al. '765 in view of Imai '864 or over Sugimoto et al. '841 or Vijyadhar et al. '765 or Imai in view of Lieberman and Brittain are maintained for reason of record.

The previous office action dated Aug. 7, 2007 provided:

- --teaching from the art that donopezil hydrochloride is soluble in chlorinated solvent and alcohol specifically, methylene chloride and methanol;
- --suggestion that spray dry a pharmaceutical product using a soluble solvent and spray drying procedure would produce an amorphous material;
  - --motivation that an amorphous material would give better dissolution.

Therefore, every element required by the <u>KSR</u> guideline has been provided. Applicants provided no factual evidence that why a process employed a simultaneously co-existed mixture

10/509,952 Art Unit: 1625

of chlorinated solvent and alcohol would produce an amorphous material which is different from the noncrystalline solid found in the prior art using a stepwise introduced dichloromethane and methanol solvents, when both solvents are known to dissolve donopezil hydrochloride.

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celia Chang, Ph. D. whose telephone number is 571-272-0679. The examiner can normally be reached on Monday through Thursday from 8:30 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet L. Andres, Ph. D., can be reached on 571-272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

OACS/Chang Jan. 14, 2008 Celia Chang Primary Examiner Art Unit 1625